Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is set to announce its fourth-quarter earnings before the market opens on Tuesday, March 24. Analysts are anticipating earnings of 4 cents per share, a significant improvement from the 6 cents per share loss reported a year ago. The consensus estimate for the company's quarterly revenue is $14.73 million, up from $7.92 million in the same period last year. On March 16, Fennec Pharmaceuticals disclosed a settlement agreement that resolved the PEDMARK patent dispute. Following this news, the company's stock rose by 1.8% to close at $7.45 on Monday. For more detailed information and analyst ratings, readers can refer to the Analyst Stock Ratings page without mentioning the source.